The Cancer Nanotechnology (CN) Program Area was formed in 2011 upon the strong advice of our EAB. CN Program Area aims are to: 1) engineer, test and deliver therapeutic anti-cancer nanoparticles;2) develop nanoscale imaging and mechanics to detect, quantify and track cancers;3) invent and refine surface, analytic and manipulative nanoscale platforms;and 4) integrate systems biology and translate promising approaches into preclinical and early phase clinical testing. The Program Area is led by Michael Teitell, MD, PhD (UCLA) and James Heath, PhD (Caltech). UCLA and Caltech have several longstanding, beneficial collaborations, including a combined Medical Scientist Training Program (MSTP), a Joint Center for ? Translational Medicine (JCTM) and an NCI-funded Center of Cancer Nanotechnology Excellence (CCNE). The CN Program Area combines the strengths of these two leading institutions to facilitate the translation of discoveries in nanotechnology into advances against cancer. As with other Program Areas, the JCCC fosters numerous interactions and many of the JCCC's Shared Resources support investigators in the CN Program Area. The CN Program Area is comprised of 26 members, including four

Public Health Relevance

Advances in nanotechnology hold great promise for the treatment and diagnosis of cancer. The Cancer Nanotechnology Program Area plays an important role in the realization of this promise by bringing nanotechnology researchers together with cancer biologists and physicians. By promoting interactions between these diverse groups, by supporting valuable shared resources and by funding innovative and collaborative research directions, it is anticipated that important new technologies and clinical advances will continue to emerge.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications